Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
T-allo10 Cell Addback Post-Αβdepleted-HSCT Drives Lasting Leukemia-Free Survival with Distinct Immune Regulation Biomarkers | Synapse
March 3, 2026
T-allo10 Cell Addback Post-Αβdepleted-HSCT Drives Lasting Leukemia-Free Survival with Distinct Immune Regulation Biomarkers
AB
Alice Bertaina
RB
Rosa Bacchetta
Lucile Packard Children's Hospital
DS
David C. Shyr
Lucile Packard Children's Hospital
Ver todo
Puntos clave
Leukemia-free survival improves significantly with T-allo10 cell addback after abdepleted-hsct.
The analysis shows a marked increase in lasting leukemia-free survival reaching 80% at one year.
Assessment using immune regulation biomarkers reveals distinct profiles after T-allo10 treatment.
Implications suggest novel therapeutic strategies may enhance outcomes in leukemia treatment.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Bertaina et al. (Sun,) studied this question.
synapsesocial.com/papers/69a760adc6e9836116a2da9f
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.145